review figures.pptx review figures.pptx v

review figures.pptx

1. New design?

2. Cas9 Embryo Transfer NHEJ Single cell embryo sgRNA1 sgRNA2 Mouse sgRNA Cas9 Single cell embryo HDR Embryo Transfer Reporter Donor vector Mouse ATG h- cDNA Holding pipette Pronuclei Fertilized egg Microinject DNA into male pronucleus Transfer to oviduct of Recipient female Transgenic over-expression via pronuclear microinjection Genetic humanization  via CRISPR/Cas9 based knock-in Genetic dysfunction via CRISPR/Cas9-based knock-out Promoter cDNA Poly A NV-NSG MHC KO mice NV-NSG FcRns KO mice NV-NSG FLT3 KO mice gRNA + Cas9 mRNA gRNA + Cas9 mRNA+ Donor DNA Knock-out Knock-in ATG NV-NSG hIL7, hIL6,IL15,hFLT3L NV-NSG hCD47 NV-NSG HLA A2 NV-NSG K14-mTslp NV-NSG tghIL2 NV-NSG tg hIL3/GMCSF fusion Transgenic over-expression e.g. e.g. e.g.

3. Human Immune System mice Human-specific Infectious Diseases (HIV, DNV, HTLV, EBV, S. Typhi, HCMV, Yellow fever, etc.) Studies of human-specific immune responses to pathogens Screening of new antiviral compounds, microbicides, and antibiotics Human-specific VAccine development Selection of antigens, including neoantigens and tumor-associated antigens Vaccine adjuvant development/screening, such as TLR agonists Vaccine platforms, such as nanovaccines , peptide vaccines, mRNA vaccine Analyses of vaccine delivery routes Tolerance and autoimmune disease Modeling and investigating the treatment of Rheumatoid Arthritis, Type 1 diabetes, IPEX, EAE/ MS, SjS , SLE, and cancer immunotherapy-induced cytotoxicity celL -based adoptive immunity Studies of the efficacy and safety (CRS, on-target off-tumor effects) of cell-based immunotherapies including CAR-T, TCR-T, CAR-NK, CAR- γδT , CAR-M, CAR-Treg, and TIL platforms Antibody-based immune therapy Investigating the efficacy and cytotoxicity of modulators specific to human immune systems, such as immune checkpoint inhibitors (ICIs), Bispecific T-cell Engagers (BITEs), neutralizing antibodies, agonist antibodies, and antibodies with ADCC, CDC, ADCP, or ADC activity